Wanbury FY26 PAT Surges 117 pc to Rs 66.1 Crore; EPS More Than Doubles
Mumbai, June 2 (TNT): Pharmaceutical company Wanbury Ltd on Wednesday reported a 116.6 per cent year-on-year jump in net profit at Rs 66.1 crore for the financial year ended March 31, 2026, driven by improved operational efficiencies, better product mix and margin expansion.
The company’s revenue from operations rose 8.5 per cent to Rs 650.3 crore in FY26 from Rs 599.5 crore in the previous fiscal, while EBITDA increased 34.9 per cent to Rs 107.7 crore.
EBITDA margin improved by 330 basis points to 16.5 per cent.
Earnings per share (EPS) more than doubled to Rs 20.55 from Rs 9.32 in FY25, reflecting strong bottom-line growth.
For the fourth quarter ended March 2026, Wanbury posted revenue of Rs 164.6 crore. Profit after tax rose 7.2 per cent year-on-year to Rs 21.7 crore, while PAT margin improved to 13.2 per cent, the Pharma company sai in a release.
The company said quarterly revenue was impacted by the West Asia crisis, which disrupted API export dispatches during March. However, gross margin expanded sharply to 60.4 per cent, supported by a favourable product mix and internal cost-efficiency initiatives.
During the year, Wanbury launched a new anaesthetic active pharmaceutical ingredient (API) from its Tanuku facility following completion of a capital expenditure programme. Commercial dispatches to Europe commenced in February 2026.
The company also strengthened its product pipeline with specialty APIs including Dextromethorphan HBr, Rivaroxaban and Sitagliptin.
Wanbury said it received zero observations during an inspection by South Korea’s Ministry of Food and Drug Safety (MFDS). Earlier, its facilities had also secured zero-observation outcomes from inspections by the USFDA and Brazil’s ANVISA regulator.
The company further received ANVISA approval for Sertraline Form II, enhancing its access to regulated international markets.
Commenting on the performance, Wanbury Director Mohan Rayana said FY26 was an important year for the company, marked by operational improvements, balance-sheet strengthening and expansion of its API and formulations businesses.
He said the company would continue its API growth journey in FY27, supported by recent launches and a strong product pipeline, while the formulations business would benefit from new products and an improved go-to-market strategy.
Established in 1988, Wanbury exports APIs to more than 50 countries and operates USFDA and EU-GMP approved manufacturing facilities at Tanuku in Andhra Pradesh and Patalganga in Maharashtra.
TNT TS
